SEARCH

SEARCH BY CITATION

References

  • 1
    American Cancer Society. Cancer Facts and Figures 2004. Atlanta, GA: American Cancer Society, 2004.
  • 2
    Jacobs I, Davies AP, Bridges J, Stabile I, Fay T, Lower A, Grudzinskas JG, Oram D. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ 1993; 306: 10304.
  • 3
    Partridge EE, Barnes MN. Epithelial ovarian cancer: prevention, diagnosis and treatment. CA Cancer J Clin 1999; 49: 297316.
  • 4
    NIH Consensus Development Panel on Ovarian Cancer. Ovarian cancer: screening, treatment and follow-up. JAMA 1995; 273: 4917.
  • 5
    Fathalla MF. Incessant ovulation — a factor in ovarian neoplasia? Lancet 1971; 2: 163.
  • 6
    Casagrande JT, Louie EW, Pike MC, Roy S, Ross RK, Henderson BE. ‘Incessant ovulation’ and ovarian cancer. Lancet 1979; 2: 1703.
  • 7
    Crammer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 1983; 71: 71721.
  • 8
    Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 1999; 91: 145967.
  • 9
    Bosetti C, Gallus S, La Vecchia C. Aspirin and cancer risk: an update to 2001. Eur J Cancer Prev 2002; 11: 53542.
  • 10
    Baron JA. Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog Exp Tumor Res 2003; 37: 124.
  • 11
    Gonzalez-Perez A, Garcia Rodriguez LA, Lopez-Ridaura R. Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer 2003; 3: 28.
  • 12
    Greenland S. Invited commentary. Am J Epidemiol 1994; 140: 2906.
  • 13
    Juni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 1999; 282: 105460.
  • 14
    Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational studies in Epidemiology (MOOSE) Group. JAMA 2000; 283: 200812.
  • 15
    Hasselblad V, Eddy DM, Kotchmar DJ. Synthesis of environmental evidence. J Air Waste Manag Assoc 1992; 42: 66271.
  • 16
    Friedenreich CM, Brant RF, Riboli E. Influence of methodologic factors in a pooled analysis of 13 case–control studies of colorectal cancer and dietary fiber. Epidemiology 1994; 5: 667.
  • 17
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 71948.
  • 18
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 17788.
  • 19
    Petitti DB. Statistical methods in meta-analysis. In Meta-Analysis, Decision Analysis and Cost-Effectiveness Analysis, ed PetittiDB. New York: Oxford University Press, 1994; 90114.
  • 20
    Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088101.
  • 21
    Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. BMJ 1997; 315: 62934.
  • 22
    Cochran WG. The combination of estimates from different experiments. Biometrics 1954; 8: 10129.
  • 23
    Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 55760.
  • 24
    Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, Hoover R, Fraumeni JF Jnr. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993; 85: 30711.
  • 25
    Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996; 32A: 17537.
  • 26
    Cibere J, Sibley J, Haga M. Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 1997; 40: 15806.
  • 27
    Katusic S, Beard CM, Kurland LT, Weis JW, Bergstralh E. Occurrence of malignant neoplasms in the Rochester, Minnesota, rheumatoid arthritis cohort. Am J Med 1985; 78 (Suppl. 1A): 505.
  • 28
    Rosenberg L. Nonsteroidal anti-inflammatory drugs and cancer. Prev Med 1995; 24: 1079.
  • 29
    Moysich KB, Mettlin C, Nataragan N. Nonsteroidal anti-inflammatory drugs and ovarian cancer risk. Am J Epidemiol 1999; S55: 149.
  • 30
    Tzonou A, Polychronopoulou A, Hsieh CC, Rebelakos A, Karakatsani A, Trichopoulos D. Hair dyes, analgesics, tranquilizers and perineal talc application as risk factors for ovarian cancer. Int J Cancer 1993; 55: 40810.
  • 31
    Lacey JV Jr, Sherman ME, Hartge P, Schatzkin A, Schairer C. Medication use and risk of ovarian carcinoma: a prospective study. Int J Cancer 2004; 108: 2816.
  • 32
    Friis S, Sorensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH. A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer 2003; 88: 6848.
  • 33
    Sorensen HT, Friis S, Norgard B, Mellemkjaer L, Blot WJ, McLaughlin JK, Ekbom A, Baron JA. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 2003; 88: 168792.
  • 34
    Fairfield KM, Hunter DJ, Fuchs CS, Colditz GA, Hankinson SE. Aspirin, other NSAIDs, and ovarian cancer risk (United States). Cancer Causes Control 2002; 13: 53542.
  • 35
    Meier CR, Schmitz S, Jick H. Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy 2002; 22: 3039.
  • 36
    Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Kato I, Koenig KL, Shore RE. Aspirin and epithelial ovarian cancer. Prev Med 2001; 33: 6827.
  • 37
    Moysich KB, Mettlin C, Piver MS, Natarajan N, Menezes RJ, Swede H. Regular use of analgesic drugs and ovarian cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10: 9036.
  • 38
    Rosenberg L, Palmer JR, Rao RS, Coogan PF, Storm BL, Zauber AG, Stolley PD, Shapiro S. A case–control study of analgesic use and ovarian cancer. Cancer Epidemiol Biomarkers Prev 2000; 9: 9337.
  • 39
    Tavani A, Gallus S, La Vecchia C, Conti E, Montella M, Franceschi S. Aspirin and ovarian cancer: an Italian case–control study. Ann Oncol 2000; 11: 11713.
  • 40
    Cramer DW, Harlow BL, Titus-Ernstoff L, Bohlke K, Welch WR, Greenberg ER. Over-the-counter analgesics and risk of ovarian cancer. Lancet 1998; 351: 1047.
  • 41
    Khuder SA, Mutgi AB. Breast cancer and NSAID use: a meta-analysis. Br J Cancer 2001; 84: 118892.
  • 42
    Wang WH, Huang JQ, Zheng GF, Lam SK, Karlberg J, Wong BC. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2003; 95: 178491.
  • 43
    Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003; 124: 4756.
  • 44
    Mahmud S, Franco E, Aprikian A. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer 2004; 90: 939.
  • 45
    Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in research. Lancet 1991; 337: 86772.
  • 46
    Simes JR. Publication bias: the case for an international registry of trials. J Clin Oncol 1986; 4: 152941.
  • 47
    Sterling TD. Publication decisions and their possible effects on inferences drawn from tests of significance — or vice versa. JASA 1959; 54: 304.
  • 48
    West SL, Savitz DA, Koch G, Sheff KL, Storm BL, Guess HA, Hartzema AG. Demographics, health behaviors, and past drug use as predictors of recall accuracy for previous prescription medication use. J Clin Epidemiol 1997; 50: 97580.
  • 49
    Patterson RE, Neuhouser ML, White E, Hunt JR, Kristal AR. Cancer-related behavior of vitamin supplement users. Cancer Epidemiol Biomarkers Prev 1998; 7: 7981.
  • 50
    Sample DA, Sinicrope PS, Wargovich MJ, Sinicrope FA. Post-study aspirin intake and factors motivating participation in a colorectal cancer chemoprevention trial. Cancer Epidemiol Biomarkers Prev 2002; 11: 2815.
  • 51
    Mills GB. Mechanisms underlying chemoprevention of ovarian cancer. Clin Cancer Res 2002; 8: 710.
  • 52
    Rodriguez-Burford C, Barnes MN, Oelschlager DK, Myers RB, Talley LI, Partridge EE, Grizzle WE. Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. Clin Cancer Res 2002; 8: 2029.
  • 53
    Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997; 57: 127680.
  • 54
    Hong W, Sporn M. Recent advantages in chemoprevention of cancer. Science 1997; 278: 10737.
  • 55
    Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 1996; 56: 45669.
  • 56
    Kawamori T, Rao C, Seibert K, Reddy B. Chemopreventive activity of celocoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998; 58: 40912.
  • 57
    Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, Speizer FE. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995; 333: 60914.